05:02 PM EDT, 08/14/2024 (MT Newswires) -- Matthew L. Posard, Director, on August 12, 2024, sold 29,881 shares in Halozyme Therapeutics ( HALO ) for $1,689,294. Following the Form 4 filing with the SEC, Posard has control over a total of 69,874 shares of the company, with 69,874 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1159036/000141588924021305/xslF345X03/form4-08142024_080823.xml